Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC
- 31 December 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 16 (4), 601-609
- https://doi.org/10.1016/j.jtho.2020.12.011
Abstract
No abstract availableFunding Information
- University of Texas MD Anderson Cancer Center
- University of Texas Southwestern Medical Center
- National Institutes of Health
This publication has 37 references indexed in Scilit:
- Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung CancerJAMA Oncology, 2016
- Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNAPLOS ONE, 2015
- Mutation tracking in circulating tumor DNA predicts relapse in early breast cancerScience Translational Medicine, 2015
- Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic VulnerabilitiesCancer Discovery, 2015
- Prognostic value of volumetric parameters of 18F-FDG PET in non-small-cell lung cancer: a meta-analysisEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Liquid Biopsies: Genotyping Circulating Tumor DNAJournal of Clinical Oncology, 2014
- The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer PatientsInternational Journal of Molecular Sciences, 2013
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Clinical Implications of p53 Mutations in Lung CancerPublished by Springer Science and Business Media LLC ,2003
- Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging The Visual Response Score and the Change in Total Lesion GlycolysisClinical Positron Imaging, 1999